Published in Gene Therapy Weekly, July 22nd, 2004
According to published research from Canada, "the receptor for the type 1 insulin-like growth factor (IGF-IR) was identified as a major regulator of the malignant phenotype and a target for cancer therapy. In the present study, a novel IGF-IR mutant consisting of the entire extracellular domain of the receptor (IGFIR933) was genetically engineered and expressed in highly metastatic H-59 murine lung carcinoma cells."
"We show here that the cells expressed a truncated heterotetramer (betam-alpha-alpha-betam) that was secreted into the medium...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.